GPR55 and fatty liver disease: In several animal models of non-alcoholic hepatic steatosis and steatohepatitis, GPR55 was found to increase lipid content by inducing de novo fatty acid synthesis and decreasing fatty acid β oxidation, which is consistent with our results [11].